Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting ... identified a protein in RSV a decade ago that looked like ...

Blue Lake’s vaccine candidate against respiratory syncytial virus (RSV), at the 2024 ISV Annual Congress in Seoul, South Korea. The oral presentation also included discussion of Phase 1 clinical data ...

Symptoms exhibited by patients are similar to those in respiratory syncytial virus ... proteins (yellow), polymerase-associated proteins (pink), glycoproteins (purple) and matrix protein (blue ...

Burden of disease of respiratory syncytial virus in infants, young children and pregnant women ... and an RSV stabilized pre-fusion subunit protein vaccine for pregnant women and people (Pfizer ...

This new vaccine will help protect newborn babies from illness caused by RSV, a common virus that affects the nose, throat, and lungs. Bakewell mum-to-be Pritee Shrestha said she was pleased to be ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

In the wake of multiple cases of human metapneumovirus (hMPV) in India, multiple questions about its causes and symptoms seem ...

The National Notifiable Diseases Surveillance System recorded 175,786 cases of respiratory syncytial virus in 2024. It is the highest number of cases recorded since the virus became notifiable.